These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 30958661)
1. Benign Pleural Mesothelial Cells Have Higher Osmotic Water Permeability than Malignant Pleural Mesothelioma Cells and Differentially Respond to Hyperosmolality. Katkova LE; Baturina GS; Bondar AA; Jagirdar RM; Hatzoglou C; Gourgoulianis KI; Solenov EI; Zarogiannis SG Cell Physiol Biochem; 2019; 52(4):869-878. PubMed ID: 30958661 [TBL] [Abstract][Full Text] [Related]
2. Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent. Jagirdar RM; Apostolidou E; Molyvdas PA; Gourgoulianis KI; Hatzoglou C; Zarogiannis SG Am J Physiol Lung Cell Mol Physiol; 2016 Mar; 310(6):L489-95. PubMed ID: 26773069 [TBL] [Abstract][Full Text] [Related]
3. Effects of pharmacological primary cilium disturbance in the context of in vitro 2D and 3D malignant pleura mesothelioma. Jagirdar RM; Pitaraki E; Kotsiou OS; Rouka E; Sinis SI; Varsamas C; Marnas P; Stergiopoulou E; Giannou A; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG Biochem Biophys Res Commun; 2023 Apr; 654():128-135. PubMed ID: 36907140 [TBL] [Abstract][Full Text] [Related]
4. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes. Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615 [TBL] [Abstract][Full Text] [Related]
5. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051 [TBL] [Abstract][Full Text] [Related]
6. Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells. Kuramitsu Y; Tominaga W; Baron B; Tokuda K; Wang Y; Kitagawa T; Nakamura K Anticancer Res; 2013 Jun; 33(6):2557-60. PubMed ID: 23749908 [TBL] [Abstract][Full Text] [Related]
12. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913 [TBL] [Abstract][Full Text] [Related]
13. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. Cury PM; Butcher DN; Corrin B; Nicholson AG J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583 [TBL] [Abstract][Full Text] [Related]
17. Pathological and molecular biological approaches to early mesothelioma. Tsujimura T; Torii I; Sato A; Song M; Fukuoka K; Hasegawa S; Nakano T Int J Clin Oncol; 2012 Feb; 17(1):40-7. PubMed ID: 22237727 [TBL] [Abstract][Full Text] [Related]
18. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249 [TBL] [Abstract][Full Text] [Related]